Abstract
Context: Owing to the pathogenic role of insulin resistance and beta-cell dysfunction in type 2 diabetes, the clinical manifestation of this disease is extremely complex and is often associated with obesity. In recent years, Roux-en-Y gastric bypass (RYGB) surgery, which was originally developed to treat morbid obesity, has been found to have therapeutic potential for diabetes. However, the underlying mechanisms of the therapeutic application of this technique are not fully known.
Objective: This review describes the technique of RYGB, including the advantages and disadvantages of the procedure. The advantages include metabolic improvement, obesity resolution, and reduction in morbidity. The disadvantages include short-term perioperative complications and long-term nutritional disorders. Finally, we provide a review of the possible underlying mechanisms leading to the resolution of type 2 diabetes symptoms after the RYGB procedure.
Conclusions: While some complications are found after RYGB, there have also been reports showing a remarkable decrease in mortality, successful weight loss, and resolution of type 2 diabetes. The actual mechanism leading to diabetes resolution remains unknown. Gastric bypass surgery is certainly an effective method to increase remission rate in a subgroup of type 2 diabetes patients with morbid obesity.
Keywords: Roux-en-Y gastric bypass, Type 2 diabetes, Morbid obesity, Weight reduction, Incretins, Beta-cell dysfunction, Insulin, Microvascular complications, Diabetic nephropathy, Hyperglycemia
Current Diabetes Reviews
Title: Gastric Bypass and Diabetes: Past, Present and Future
Volume: 7 Issue: 5
Author(s): Tse-I Lee, Jui-Hung Chen, Ting-Chia Weng, Keong Chong, Wei-Jei Lee and Lee-Ming Chuang
Affiliation:
Keywords: Roux-en-Y gastric bypass, Type 2 diabetes, Morbid obesity, Weight reduction, Incretins, Beta-cell dysfunction, Insulin, Microvascular complications, Diabetic nephropathy, Hyperglycemia
Abstract: Context: Owing to the pathogenic role of insulin resistance and beta-cell dysfunction in type 2 diabetes, the clinical manifestation of this disease is extremely complex and is often associated with obesity. In recent years, Roux-en-Y gastric bypass (RYGB) surgery, which was originally developed to treat morbid obesity, has been found to have therapeutic potential for diabetes. However, the underlying mechanisms of the therapeutic application of this technique are not fully known.
Objective: This review describes the technique of RYGB, including the advantages and disadvantages of the procedure. The advantages include metabolic improvement, obesity resolution, and reduction in morbidity. The disadvantages include short-term perioperative complications and long-term nutritional disorders. Finally, we provide a review of the possible underlying mechanisms leading to the resolution of type 2 diabetes symptoms after the RYGB procedure.
Conclusions: While some complications are found after RYGB, there have also been reports showing a remarkable decrease in mortality, successful weight loss, and resolution of type 2 diabetes. The actual mechanism leading to diabetes resolution remains unknown. Gastric bypass surgery is certainly an effective method to increase remission rate in a subgroup of type 2 diabetes patients with morbid obesity.
Export Options
About this article
Cite this article as:
Lee Tse-I, Chen Jui-Hung, Weng Ting-Chia, Chong Keong, Lee Wei-Jei and Chuang Lee-Ming, Gastric Bypass and Diabetes: Past, Present and Future, Current Diabetes Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339911797415611
DOI https://dx.doi.org/10.2174/157339911797415611 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Current Diabetes Reviews The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies
Current Drug Metabolism Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview
Current Diabetes Reviews Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design The Role of Angiotensin-Converting Enzyme in Immunity: Shedding Light on Experimental Findings
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for New Anti-Diabetic Agent
Current Topics in Medicinal Chemistry Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006
Current Hypertension Reviews